The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Bicycle Therapeutics plc(NASDAQ:BCYC) 
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express...
Website: http://bicycletherapeutics.com
Founded: 2009
IPO Price: $14 (May 23, 2019)
Full Time Employees: 81
CEO: Kevin Lee
Sector: Healthcare
Industry: Biotechnology
Bicycle Therapeutics plc Number of Twitter Followers
Bicycle Therapeutics plc Days Payable Outstanding ttm (DPO)
Bicycle Therapeutics plc Days Receivable Outstanding ttm (DSO)
Bicycle Therapeutics plc Op Cashflow Per Share ttm
Bicycle Therapeutics plc Free Cashflow Per Share ttm
Bicycle Therapeutics plc Cash Per Share ttm
Bicycle Therapeutics plc P/S ratio ttm
Bicycle Therapeutics plc (GAAP) P/E ratio ttm
Bicycle Therapeutics plc P/B ratio ttm
No extra charts and metrics for this ticker.